Hematological Malignancies

References

• Van den Berghe, H., Cassiman, J.J., David, G., Fryns, J.P., Michaux, J.L. and Sokal, G. (1974) "Distinct haematological disorder with deletion of the long arm of no.5 chromosome", Nature 251, 437–438.
   PubMed Web of Science ®Google Scholar
• Jaffe, E.S., Harris, N.L., Stein, H. and Vardiman, J.W. (2001) World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haemato poetic and Lymphoid Tissues (IARC Press, Lyon).
   Google Scholar
• Bennett, J.M., Catovsky, D., Daniel, M-T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. and Sultan, C. (1982) "Proposals for the classification of the myelodysplastic syndromes", British Journal of Haematology 51, 189–199.
   PubMed Web of Science ®Google Scholar
• Germing, U., Gattermann, N., Strupp, C., Aivado, M. and Aul, C. (2000) "Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients", Leukemia Research 24, 983–992.
   PubMed Web of Science ®Google Scholar
• Van den Berghe, H., Vermaelen, K., Mecucci, C., Barbieri, D. and Tricot, G. (1985) "The 5q-anomaly", Cancer Genetics and Cytogenetics 17, 189–255.
   PubMed Web of Science ®Google Scholar
• Mathew, P., Tefferi, A., Dewald, G.W., Goldberg, J., Hoagland, H.C. and Noel, E (1993) "The 5q- syndrome: a single institution study of 43 consecutive patients", Blood 81, 1040–1045.
   PubMed Web of Science ®Google Scholar
• Giagounidis, A.A.N., Germing, U., Haase, S., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H., Aivado, M. and Aul, C. (2004) "Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31", Leukemia 18, 113–119.
   PubMed Web of Science ®Google Scholar
• Pedersen, B. and Jensen, M. (1991) "Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients", Leukemia 5, 566–573.
   PubMed Web of Science ®Google Scholar
• Kerkoffs, H., Hagemeijer, A., Leeksma, C.H.W., Abels, J., Den Ottolander, G.J., Somers, R., Gerrits, W.B.J., Langenhuiyen, M.M.A.C., von dem Borne, A.E.G.Jr., van Hemel, JO. and Geraedts, J.P.M. (1982) "The 5q-chromosome abnormality in haematological disorders: a collaborative study of 34 cases from the Netherlands", British Journal of Haematology 52, 365–381.
   PubMed Web of Science ®Google Scholar
• Lewis, S., Oscier, D., Boultwood, J., Ross, F., Fitchett, M., Rack, K., Abrahamson, G., Buckle, V. and Wainscoat, J.S. (1995) "Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion", American Journal of Hematology 49, 470–477.
   Web of Science ®Google Scholar
• Boultwood, J., Lewis, S. and Wainscoat, J.S. (1994) "The 5q- syndrome", Blood 84, 3253–3260.
   PubMed Web of Science ®Google Scholar
• Boultwood, J., Fidler, C., Strickson, A.J., Watkins, F., Gama, S., Kearney, L., Tosi, S., Kasprzyk, A., Cheng, J-F., Jaju, R.J. and Wainscoat, J.S. (2002) "Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome", Blood 99, 4638–4641.
   PubMed Web of Science ®Google Scholar
• Pellagatti, A., Esoof, N., Watkins, F., Langford, C.F., Vetrie, D., Campbell, L., Fidler, C., Cavenagh, J., Eagleton, H., Gordon, P., Woodcock, B., Pushkaran, B., Kwan, M., Wainscoat, J.S., Boultwood, J. Gene expression profiling in the myelodys-plastic syndromes using cDNA microarray technology. British Journal of Haematology (in press).
   Web of Science ®Google Scholar
• Zhao, N., Stoffel, A., Wang, P.W., Eisenbart, J.D., Espinosa, DI, R., Larson, R.A. and Le Beau, M.M. (1997) "Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5 Mb and preparation of a PAC-based physical map", Proceedings of the National. Academy of Sciences of the USA 94, 6948–6953.
   PubMed Web of Science ®Google Scholar
• Giagounidis, A.A.N., Haase, S., Peceny, R., Germing, U., Aivado, M., Schroeder, M. and Aul, C. (2002) "AC133-positive cells carry the del(5q) in the clinical 5q- syndrome", Onkologie 25\(Suppl 4), XII + 304 (abstract).
   Google Scholar
• Nilsson, L., Astrand-Grundström, I., Arvidsson, I., Jacobsson, B., Hellström-Lindberg, E., Hast, R. and Jacobsen, S.E. (2000) "Isolation and characterization of hematopoietic progenitor/ stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level", Blood 96, 2012–2021.
   PubMed Web of Science ®Google Scholar
• Nilsson, L., Astrand-Grundström, I., Anderson, K., Arvidsson, I., Hokland, P., Bryder, D., Kjeldsen, L., Johansson, B., Hellström-Lindberg, E., Hast, R. and Jacobsen, S.E.W. (2002) "Involvement and functional impairment of the CD34+ CD38— Thy1+ hematopoietic stem cell pool in myelo-dysplastic syndromes with trisomy 8", Blood 100,259–267.
   PubMed Web of Science ®Google Scholar
• Dewald, G.W., Davis, M.P., Pierre, R.V., O'Fallon, J.R. and Hoagland, H.C. (1985) "Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5", Blood 66, 189–197.
   PubMed Web of Science ®Google Scholar
• Cermak, J., Michalova, K., Brezinova, J. and Zemanova, Z. (2000) "A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syn-drome", Leukemia Research 27, 221–229.
   Google Scholar
• Aul, C., Gatterman, N., Heyll, A., Germing, U., Derigs, G. and Schneider, W. (1992) "Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system", Leukemia 6, 52–59.
   PubMed Web of Science ®Google Scholar
• Giagounidis, A.A.N., Haase, S., Germing, U., Hildebrandt, B., Heinsch, M., Aivado, M., Schroeder, M. and Aul, C. (2002) "Low-dose cytarabine in the treatment of patients with the 5q- syndrome", Onkologie 25\(Suppl 4), XII + 304 (abstract).
   Google Scholar
• Juneja, H.S., Jodhani, M., Gardner, F.H., Trevarthen, D. and Schottstedt, M. (1994) "Low-dose ara-C consistently induces hematologic responses in the clinical 5q- syndrome", American Journal of Hematology 46, 338–342.
   PubMed Web of Science ®Google Scholar
• Aul, C., Runde, V. and Gattermann, N. (1993) "All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study", Blood 82, 2967–2974.
   PubMed Web of Science ®Google Scholar
• Giagounidis, A.A.N., Germing, U., Haase, S., Schlegelberger, B., Schoch, C., Kreipe, H.H., Aivado, M., Strupp, C., Liibbert, M., Lipke, J., Fetscher, S., Wysk, J., Grabenhorst, U., Schmid, M., Grips, K., Kimmich, M., Burstedde, V, Ganser, A. and Aul, C. (2003) "Treatment of the 5q- syndrome with all-trans-retinoic acid: a phase II study of the German MDS study group", Onkologie 26\(Suppl 5), VIII 248 (abstract).
   Google Scholar
• List, A.F., Kurtin, S., Glinsmann-Gibson, B., Bellamy, W., Buresh, A., Mahadevan, D., Rimsza, L., Waddleton, D. and Knight, R.D. (2003) "Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS)", Blood 101 (Suppl), 641 (abstract).
   Google Scholar
• List, A.F., Kurtin, S.E., Glinsmann-Gibson, B.J., Bellamy, W.T., Buresh, A.J., Waddleton, D. and Knight, R. (2002) "High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelo-dysplastic syndrome", Blood 100\(Suppl 1), 353 (abstract).
   PubMedGoogle Scholar
• Stewart, B., Verdugo, M., Guthrie, K.A., Appelbaum, F. and Deeg, H.J. (2003) "Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del(5q) karyotypes", British Journal of Haematology 123, 879–885.
   PubMed Web of Science ®Google Scholar